CMPX צמיחת רווח נקי למניה השנה Compass Therapeutics

Compass Therapeutics is integrating ESG principles into biopharmaceuticals, adhering to testing ethics and environmental sustainability. Compass Therapeutics is developing a synergistic environment for combined cancer immunotherapy. The GURU.Markets platform contains the 12-month earnings per share growth rates, where the -21.00 metric determines this level. Business stability relies on patent protection for antibodies, although ultimate resilience depends on clinical trial outcomes.

This indicator measures the year-over-year dynamics of net profit per share, reflecting the efficiency of business capitalization through changes in EPS. For Compass Therapeutics (CMPX), this annual EPS percentage change depends critically on clinical trial costs and FDA regulatory decisions, where any deviations from antibody forecasts instantly translate into earnings volatility.